Doença rara de origem genética que afeta o sistema digestivo, causando sintomas variados como má absorção, dor abdominal e distensão. O diagnóstico precoce e o manejo multidisciplinar são cruciais para melhorar a qualidade de vida.
Introdução
O que você precisa saber de cara
Visão geral
A Doença genética gastroenterológica é uma condição rara que afeta o sistema digestivo. Por ser uma doença genética, sua origem está em alterações no material hereditário (DNA), que podem ser transmitidas de pais para filhos. Ainda não há dados precisos sobre quantas pessoas são afetadas por essa condição no Brasil ou no mundo.[1]
Sinais e sintomas
Até o momento, não há uma lista específica de sinais e sintomas documentada para esta doença. Os sintomas podem variar amplamente de pessoa para pessoa, dependendo das alterações genéticas envolvidas. É importante que qualquer desconforto gastrointestinal persistente seja avaliado por um médico.[1]
Causas genéticas
Esta condição é causada por alterações (mutações) em genes que ainda não foram completamente identificados. Até o momento, não há um gene específico associado a esta doença nos bancos de dados científicos oficiais. A herança (como a condição é passada de pais para filhos) também não foi determinada.[1][2]
Diagnóstico
O diagnóstico é baseado na avaliação clínica realizada por um médico especialista, geralmente um gastroenterologista ou geneticista. Exames de imagem, endoscopia e biópsias podem ser utilizados para investigar os sintomas. Testes genéticos podem ajudar a confirmar o diagnóstico, mas atualmente não há um teste genético específico amplamente disponível para esta condição.[1][2]
Tratamento e manejo
Não existe um tratamento único ou padronizado para esta doença. O manejo é individualizado e focado no alívio dos sintomas de cada paciente. Isso pode incluir medicamentos para controle de dor, náuseas ou diarreia, além de suporte nutricional. O acompanhamento regular com uma equipe multidisciplinar (médicos, nutricionistas, psicólogos) é fundamental.[1]
Tratamentos citados na literatura
Não há medicamentos ou tratamentos específicos citados na literatura científica para esta condição até o momento. Qualquer informação sobre tratamentos deve ser discutida diretamente com seu médico.[1]
Prognóstico e qualidade de vida
O prognóstico (evolução esperada da doença) varia muito de pessoa para pessoa, dependendo da gravidade dos sintomas e da resposta ao tratamento. Com acompanhamento médico adequado e suporte multidisciplinar, muitas pessoas conseguem manter uma boa qualidade de vida. Não há dados específicos sobre a expectativa de vida para esta condição.[1]
Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.
A expressão **doença genética gastroenterológica** não é o nome de uma única doença, mas sim um grupo que reúne várias condições genéticas raras que podem atingir o aparelho digestivo. Por se tratar de uma categoria ampla, os sintomas dependem da condição específica que a pessoa apresenta, podendo envolver órgãos como fígado, pâncreas ou intestinos. O acompanhamento e os exames necessários variam para cada paciente, dependendo da confirmação do diagnóstico exato por médicos especialistas. Esta categoria genérica não possui protocolo de tratamento exclusivo ou medicamentos dispensados pelo SUS catalogados, e o cuidado ocorre pela rede pública conforme a condição identificada.
Doença rara de origem genética que afeta o sistema digestivo, causando sintomas variados como má absorção, dor abdominal e distensão. O diagnóstico precoce e o manejo multidisciplinar são cruciais para melhorar a qualidade de vida.
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Doença genética gastroenterológica
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Pesquisa e ensaios clínicos
Nenhum ensaio clínico registrado para esta condição.
Publicações mais relevantes
Prevalence of germline pathogenic variants in cancer predisposition genes in the Japanese population.
Germline pathogenic variants (GPVs) in cancer predisposition genes increase cancer risk, but their population-level prevalence in Japan remains unclear. To estimate the prevalence of GPV carriers of hereditary cancer predisposition syndromes (HCPSs) in the Japanese population. A cross-sectional analysis of the Tohoku Medical Megabank Organization datasets was conducted to assess allele frequencies of rare GPVs, estimate carrier prevalence, and describe variant distribution. The cumulative allele frequency of rare GPVs of cancer predisposing genes was 1.47% for autosomal dominant and 3.20% for autosomal recessive diseases. The estimated prevalence of GPV carriers was 2.90% (1 in 35 individuals) and 0.10% (1 in 977 individuals) for autosomal dominant HCPSs and autosomal recessive HCPSs, respectively; ~6.19% of the population (1 in 16 individuals) were carriers. Variant types differed across genes, and hotspot variants had a significant impact on allele frequencies. Moreover, 47 structural variants (0.28%) having the potential to cause structural disruption were identified. Allele frequency analysis of rare GPVs of cancer predisposition genes offered valuable insight into the prevalence of GPV carriers of HCPSs in the Japanese population. Hotspot variants may represent founder mutations within specific ethnic groups, and their presence or absence could affect gene-specific allele frequencies.
Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report.
The BRAF V600E mutation is a rare genetic alteration in cholangiocarcinoma for which sequential therapy with immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors may be effective. However, the full spectrum of adverse events associated with the sequential use of these agents remains unclear. Hemophagocytic lymphohistiocytosis (HLH) is a fatal cytokine release syndrome that can be triggered by a cytokine storm. A 49-year-old man underwent left lateral hepatectomy and adjuvant chemotherapy for cholangiocarcinoma and subsequently developed lymph node recurrence. The patient initially received systemic chemotherapy with gemcitabine, cisplatin, and S-1; however, due to disease progression, the regimen was switched to gemcitabine, cisplatin, and durvalumab. After these treatments, a BRAF V600E mutation was identified through comprehensive gene panel testing, leading to the initiation of BRAF and MEK inhibitors. However, 3 months later, the patient presented to the emergency department of Steel Memorial Muroran Hospital with fever and fatigue in June 2024. He was initially diagnosed with septic shock but was unresponsive to broad-spectrum antibiotics. Laboratory tests revealed elevated ferritin levels, elevated soluble interleukin-2 receptor levels, and Epstein-Barr Virus (EBV)-DNA. HLH was diagnosed, and multidisciplinary treatment, including steroid pulse therapy, was initiated. The patient's condition improved dramatically, and he survived. We report a rare case of cholangiocarcinoma with suspected EBV-associated HLH that developed after sequential therapy with an ICI and BRAF/MEK inhibitors. Clinicians should consider HLH as a differential diagnosis in patients with a history of ICI therapy who present with severe unexplained inflammation or shock. Prompt diagnosis and multidisciplinary management are crucial to prevent death.
Contribution of germline and somatic mutations to risk of neuromyelitis optica spectrum disorder.
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by optic neuritis and transverse myelitis, with an unclear genetic background. A genome-wide meta-analysis of NMOSD in Japanese individuals (240 patients and 50,578 controls) identified significant associations with the major histocompatibility complex region and a common variant close to CCR6 (rs12193698; p = 1.8 × 10-8, odds ratio [OR] = 1.73). In single-cell RNA sequencing (scRNA-seq) analysis (25 patients and 101 controls), the CCR6 risk variant showed disease-specific expression quantitative trait loci effects in CD4+ T (CD4T) cell subsets. Furthermore, we detected somatic mosaic chromosomal alterations (mCAs) in various autoimmune diseases and found that mCAs increase the risk of NMOSD (OR = 3.37 for copy number alteration). In scRNA-seq data, CD4T cells with 21q loss, a recurrently observed somatic event in NMOSD, showed dysregulation of type I interferon-related genes. Our integrated study identified novel germline and somatic mutations associated with NMOSD pathogenesis.
Recent advances in the treatment of FGFR-altered cholangiocarcinoma.
Cholangiocarcinoma (CCA) is a rare, highly lethal biliary malignancy comprising intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes, with a rising global incidence. Surgery is the only curative option, yet most patients present with advanced disease, making systemic therapy the mainstay. Molecular profiling has revealed marked heterogeneity, and fibroblast growth factor receptor 2 (FGFR2) fusions in iCCA represent one of the most actionable targets. An extensive literature search was performed in PubMed/MEDLINE, Embase, and ClinicalTrials.gov to identify preclinical studies, clinical research, and clinical trials evaluating FGFR inhibitor therapy in CCA. This review summarizes FGFR signaling biology, the prevalence and diagnostic challenges of FGFR2 fusions, and clinical evidence for FGFR inhibitors. Resistance mechanisms, diagnostic strategies, toxicity profiles, and ongoing trials are also reviewed. FGFR inhibitors are transitioning from experimental to established targeted options, underscoring the need for routine molecular profiling and optimized fusion detection. Key challenges include overcoming resistance, refining patient selection, and defining the role of FGFR inhibition in combination strategies and earlier-line or perioperative settings. Further evidence is needed to clarify long-term clinical benefit in FGFR2-altered CCA.
Novel organoid-based exploration reveals the role of LMTK3/FADS2 signaling in metastatic breast cancer progression in felines and humans.
Cancer research in veterinary medicine is still under development compared to human medicine. Feline breast cancer (FBC) is highly malignant, intractable, and has the potential to become a valuable model for human metastatic BC (HBC). We developed primary FBC organoids and analyzed their morphology, gene expression patterns, and response to anti-cancer drugs. FBC organoids recapitulated the structure and behavior of tumor cells, exhibiting diverse hormone receptor expressions and tumorigenic potential. Moreover, varying sensitivities to chemotherapies and targeted drugs were evident across FBC organoid lines. Furthermore, LMTK3 was significantly upregulated in FBC organoids compared to feline normal mammary organoids (FNM). Further, LMTK3/FADS2 pathway was revealed to be implicated in progression by influencing cell proliferation, invasion, and apoptosis of FBC organoids. Treatment with C28 (an LMTK3 inhibitor) also prevented cell viability of human BC organoids. The survival time of human BC patients with high co-expression of LMTK3 and FADS2 was shorter than that with low co-expression. These findings highlight the importance of LMTK3/FADS2 pathway in BC progression and indicate that FBC organoids might help to do comparative research and identify conserved mechanisms between HBC and FBC.
Publicações recentes
Ver todas no PubMed📚 EuropePMCmostrando 98
Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report.
Cancer reports (Hoboken, N.J.)Recent advances in the treatment of FGFR-altered cholangiocarcinoma.
Expert opinion on pharmacotherapyPrevalence of germline pathogenic variants in cancer predisposition genes in the Japanese population.
Japanese journal of clinical oncologyNovel organoid-based exploration reveals the role of LMTK3/FADS2 signaling in metastatic breast cancer progression in felines and humans.
Scientific reportsPAGE4, upregulated in a novel iPSC-derived hepatoblastoma model, promotes hepatoblastoma progression.
Biochemical and biophysical research communicationsGAPO syndrome: a comprehensive examination and review of 105 clinical cases.
Journal of medical genetics[Chemotherapeutic Strategy for Metastatic or Recurrent Appendiceal Adenocarcinoma].
Gan to kagaku ryoho. Cancer & chemotherapyComparison of the clinical characteristics of children with Silver-Russell syndrome genetically confirmed or not and their response to growth hormone therapy: a national multicenter study.
Journal of pediatric endocrinology & metabolism : JPEMMultiple Desmoplastic Small Round Cell Tumor in the Intestine: A Case Report.
Surgical case reportsContribution of germline and somatic mutations to risk of neuromyelitis optica spectrum disorder.
Cell genomicsUndifferentiated spindle cell sarcoma at the anastomosis after ileocecal resection for colon cancer: A case report.
International journal of surgery case reportsA Case of Advanced Biliary Tract Cancer With EGFR Amplification That Responded to Necitumumab.
Cancer reports (Hoboken, N.J.)Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
NEJM evidenceLysinuric Protein Intolerance: Not Only a Disorder for Pediatric Nephrologists - Case Report.
NephronPharmacogenomic Assessment of Genes Implicated in Thiopurine Metabolism and Toxicity in a UK Cohort of Pediatric Patients With Inflammatory Bowel Disease.
Inflammatory bowel diseasesPathogenesis of chronic enteropathy associated with the SLCO2A1 gene: Hypotheses and conundrums.
World journal of gastroenterologyUpdated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision.
The British journal of surgeryMultiple duodenal epithelial tumors in a patient with polymerase proofreading-associated polyposis in POLE variant.
Clinical journal of gastroenterologyRefractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges.
Frontiers in oncologySacral agenesis without maternal diabetes: a case report.
Annals of medicine and surgery (2012)Case report: Novel insights into hemorrhagic destruction of the brain, subependymal calcification, and cataracts disease.
Frontiers in pediatricsDual role of autotaxin as novel biomarker and therapeutic target in pancreatic neuroendocrine neoplasms.
Cancer scienceCathepsin C role in inflammatory gastroenterological, renal, rheumatic, and pulmonary disorders.
BiochimieThe comprehensive review of gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) from diagnosis and treatment.
Annals of gastroenterological surgeryA case of hepatic anisakidosis caused by Anisakis pegreffii mimicking liver cancer.
Parasites, hosts and diseasesEsophagogastric Varix Caused by Extrahepatic Portal Vein Obstruction with Essential Thrombocythemia: A Case Report.
Journal of Nippon Medical School = Nippon Ika Daigaku zasshiDerivation of a new model of lung adenocarcinoma using canine lung cancer organoids for translational research in pulmonary medicine.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieHealthcare resource utilization of patients with mitochondrial disease in an outpatient hospital setting.
Orphanet journal of rare diseasesLoss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations.
GenesCase report: Gastroenterological management in a case of cardio-facio-cutaneous syndrome.
Frontiers in pediatricsInvolvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor.
Cancer sciencePartial hepatectomy for a patient with Rendu-Osler-Weber disease: a case report.
Surgical case reportsAGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
GastroenterologyA Unique Observation of a Patient with Vulto-van Silfhout-de Vries Syndrome.
Diagnostics (Basel, Switzerland)Rapid Weight Loss and Severe Failure to Thrive Mimicking Lipodystrophy Syndrome in a 1-Year-Old Taiwanese Girl with Costello Syndrome.
Children (Basel, Switzerland)Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis.
BMC microbiologyVagus nerve stimulation for conservative therapy-refractive epilepsy and depression.
Laryngo- rhino- otologieChemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer.
Anticancer researchThe Association Between Onset of Staphylococcal Non-menstrual Toxic Shock Syndrome With Inducibility of Toxic Shock Syndrome Toxin-1 Production.
Frontiers in microbiologyA Rare Case of Upper Gastrointestinal Bleeding: Osler-Weber-Rendu Syndrome.
Medicina (Kaunas, Lithuania)Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan.
Scientific reportsCorrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
Journal of hepatologyIncreased intratumor heterogeneity, angiogenesis and epithelial to mesenchymal transition pathways in metaplastic breast cancer.
American journal of cancer researchOutcomes After Living Donor Liver Transplantation in Pediatric Patients with Inherited Metabolic Diseases.
Annals of transplantation[Hepatic glycogen storage diseases: Symptoms, management and associated mutations].
Andes pediatrica : revista Chilena de pediatriaPD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer.
Scientific reportsAn international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.
Journal of hepatologyFrequency and clinical characteristics of special types of achalasia in Japan: A large-scale, multicenter database study.
Journal of gastroenterology and hepatologyLiver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome.
Diagnostics (Basel, Switzerland)Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
Japanese journal of clinical oncologySarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses.
International journal of cancerDefinition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverAcute Pancreatitis: Genetic Risk and Clinical Implications.
Journal of clinical medicineDCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
Hepatology (Baltimore, Md.)Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement.
NeuroendocrinologyNon-Invasive Assessment and Management of Liver Involvement in Adults With Alpha-1 Antitrypsin Deficiency.
Chronic obstructive pulmonary diseases (Miami, Fla.)Laparoscopic surgery for familial multiple gastrointestinal stromal tumors with germ line c-kit gene mutation.
Asian journal of endoscopic surgeryHistopathologic Analysis of Signet-ring Cell Carcinoma In Situ in Patients With Hereditary Diffuse Gastric Cancer.
The American journal of surgical pathology[Personalized treatment of cholangiocellular carcinoma (CCA)].
Der InternistOutcomes of Liver Transplant for Adults With Wilson's Disease.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyQuantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
Cancer scienceDetection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
Methods in enzymologyPeutz-Jeghers syndrome in dermatology.
Acta dermatovenerologica Alpina, Pannonica, et AdriaticaCooccurrence of Two Different Genetic Diseases: A Case of Valproic Acid Hepatotoxicity in Nicolaides-Baraitser Syndrome (SMARCA2 Mutation)-Due to a POLG1-Related Effect?
NeuropediatricsDifferentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario.
Frontiers in endocrinologyCXCL12 expression in intrahepatic cholangiocarcinoma is associated with metastasis and poor prognosis.
Cancer scienceMolecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features.
Scientific reportsIntegrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Cold Spring Harbor molecular case studiesResponsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain.
Cancer immunology researchPeripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association.
Acta bio-medica : Atenei Parmensis[Practical Genetic Testing in Gastroenterology].
Deutsche medizinische Wochenschrift (1946)Growth rate and myofibroblast differentiation of desmoid fibroblast-like cells are modulated by TGF-β signaling.
Histochemistry and cell biologyMedullary carcinoma of the pancreas radiologically followed up as a cystic lesion for 9 years: a case report and review of the literature.
Surgical case reportsPhytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial.
Pharmacological researchMassive intussusception caused by a solitary Peutz-Jeghers type hamartomatous polyp.
Annals of the Royal College of Surgeons of EnglandModifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course.
Endocrine-related cancerRegorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Cell cycle (Georgetown, Tex.)Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors.
OncotargetAnalysis of lifestyle factors in patients with concomitant chronic pancreatitis and liver cirrhosis.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]Primary Gastric ALK-negative EBV-negative Anaplastic Large Cell Lymphoma Presenting with Iron Deficiency Anemia.
In vivo (Athens, Greece)Analysis of Newly Identified and Rare Synonymous Genetic Variants in the RET Gene in Patients with Medullary Thyroid Carcinoma in Polish Population.
Endocrine pathologySpecifying the molecular pattern of sporadic parathyroid tumorigenesis-The Y282D variant of the GCM2 gene.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieA Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer.
EBioMedicineClinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.
OncotargetFamilial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome.
Anticancer researchGenome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.
Nature geneticsDynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus.
Nature communicationsFunctional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk.
OncotargetClinicopathological Characteristics, Surgery and Survival Outcomes of Patients with Duodenal Gastrointestinal Stromal Tumors.
DigestionAblation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas.
Scientific reportsClinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidates.
Cancer scienceShort article: Relapsing Whipple's disease: a case report and literature review.
European journal of gastroenterology & hepatologyHereditary Gastric Cancer Syndromes.
Surgical oncology clinics of North AmericaSigns and genetics of rare cancer syndromes with gastroenterological features.
World journal of gastroenterologyA case of early onset rectal cancer of Lynch syndrome with a novel deleterious PMS2 mutation.
Japanese journal of clinical oncologyThe Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target.
Molecular and cellular therapies[A case of malignant peritoneal mesothelioma without deletion of p16].
Gan to kagaku ryoho. Cancer & chemotherapyUnique genomic profile of fibrolamellar hepatocellular carcinoma.
GastroenterologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Doença genética gastroenterológica.
É de uma associação que acompanha esta doença? Fale com a gente →
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Ainda não achamos doenças com sintomas parecidos o suficiente.
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
É uma categoria da base Orphanet (ORPHA:165652) que agrupa diversas doenças raras e congênitas que afetam o aparelho digestivo. Por ser uma categoria ampla, abrange diferentes condições que afetam órgãos como estômago, fígado, pâncreas e intestinos.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
3 fontes citadas no texto · 6 publicações do grafo RarasNet (PubMed) · 3 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (2026). Doença genética gastroenterológica. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/doenca-genetica-gastroenterologica
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Doença genética gastroenterológica
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Dado público estruturado
- fonte: Wikidata
